113 related articles for article (PubMed ID: 2592819)
61. [Usefulness of oral rehydration solution for hydration in cancer chemotherapy: toward the application of outpatient chemotherapy with high-dose Cisplatin therapy-].
Sato J; Kudo K; Hino K; Takahashi K
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1471-6. PubMed ID: 21918344
[TBL] [Abstract][Full Text] [Related]
62. [Studies on serum and urinary alpha 1-microglobulin levels as parameter of the renal function--renal function observed after CDDP administration].
Ujiie T; Maruta H; Ito N
Hinyokika Kiyo; 1988 May; 34(5):790-6. PubMed ID: 2459938
[TBL] [Abstract][Full Text] [Related]
63. High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary results.
Bruzzone M; Conte PF; Chiara S; Carnino F; Giaccone G; Conio A; Bentivoglio G; Pescetto G; Rosso R
Chemioterapia; 1985 Apr; 4(2):139-42. PubMed ID: 3891114
[TBL] [Abstract][Full Text] [Related]
64. [Phase II studies of a single agent and a cis-platinum-based two-drug combination in patients with non-small cell lung cancer].
Yamamoto M; Furuse K; Fukuoka M; Kawahara M; Arai R; Kodama N; Takada M; Negoro S; Matsui K; Ryu S
Gan To Kagaku Ryoho; 1988 Mar; 15(3):487-92. PubMed ID: 2831821
[TBL] [Abstract][Full Text] [Related]
65. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
Merouani A; Davidson SA; Schrier RW
Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
[TBL] [Abstract][Full Text] [Related]
66. Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial.
Somlo G; Doroshow JH; Lev-Ran A; Ahn DC; Hwang L; Raschko JW; Forman SJ; Margolin KA; Morgan RJ; Leong LA
J Clin Oncol; 1995 May; 13(5):1231-7. PubMed ID: 7738626
[TBL] [Abstract][Full Text] [Related]
67. [Nephrotoxicity of a Short Hydration Method for the Cisplatin Regimen in Patients with Gastric Cancer].
Kishi K; Saito T; Mikamori M; Ohtsuka M; Furukawa K; Suzuki Y; Tei M; Tanemura M; Akamatsu H
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2069-2071. PubMed ID: 30692287
[TBL] [Abstract][Full Text] [Related]
68. Prevention by urinastatin of cis-diamminedichloroplatinum-induced nephrotoxicity in rabbits: comparison of urinary enzyme excretions and morphological alterations by electron microscopy.
Kobayashi H; Ohi H; Terao T
Asia Oceania J Obstet Gynaecol; 1991 Sep; 17(3):277-88. PubMed ID: 1953441
[TBL] [Abstract][Full Text] [Related]
69. Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer.
Erlichman C; Soldin SJ; Thiessen JJ; Sturgeon JF; Fine S
Cancer Chemother Pharmacol; 1987; 19(1):75-9. PubMed ID: 3815729
[TBL] [Abstract][Full Text] [Related]
70. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
[TBL] [Abstract][Full Text] [Related]
71. Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin.
Reece PA; Stafford I; Russell J; Gill PG
J Clin Oncol; 1986 Sep; 4(9):1392-8. PubMed ID: 3746376
[TBL] [Abstract][Full Text] [Related]
72. Expression of gamma-glutamyl transpeptidase in stage III and IV ovarian surface epithelial carcinomas does not alter response to primary cisplatin-based chemotherapy.
Hanigan MH; Frierson HF; Taylor PT
Am J Obstet Gynecol; 1998 Aug; 179(2):363-7. PubMed ID: 9731839
[TBL] [Abstract][Full Text] [Related]
73. Intratumor cisplatin nephrotoxicity in combined laser-induced thermal therapy for cancer treatment.
Palumbo MN; Cervantes O; Eugênio C; Hortense FTP; Ribeiro JC; Paolini AAP; Tedesco AC; Sercarz JA; Paiva MB
Lasers Surg Med; 2017 Oct; 49(8):756-762. PubMed ID: 28598516
[TBL] [Abstract][Full Text] [Related]
74. [Clinical study of nephrotoxicity following cis-diamminedichloroplatinum (II) (CDDP) combination chemotherapy assessed by 131I-OIH renogram].
Shirasaka K
Nihon Igaku Hoshasen Gakkai Zasshi; 1990 Dec; 50(12):1580-9. PubMed ID: 2089371
[TBL] [Abstract][Full Text] [Related]
75. Renal tolerance of cisplatin in patients more than 80 years old.
Thyss A; Saudes L; Otto J; Creisson A; Gaspard MH; Dassonville O; Schneider M
J Clin Oncol; 1994 Oct; 12(10):2121-5. PubMed ID: 7931482
[TBL] [Abstract][Full Text] [Related]
76. Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity.
Takagi A; Miyoshi T; Hayashi T; Koizumi H; Tsumagari K; Yokota C; Nakano T; Matsuo K; Egawa T
Sci Rep; 2024 May; 14(1):10511. PubMed ID: 38714773
[TBL] [Abstract][Full Text] [Related]
77. Cisplatin-induced nephrotoxicity and the protective effect of fosfomycin on it as demonstrated by using a crossover study of urinary metabolite levels.
Hayashi M; Numaguchi M; Watabe H; Enomoto H; Yaoi Y
Acta Obstet Gynecol Scand; 1997 Jul; 76(6):590-5. PubMed ID: 9246969
[TBL] [Abstract][Full Text] [Related]
78. The role of complement activation, detected by urinary C5b-9 and urinary factor H, in the excretion of urinary albumin in cisplatin nephropathy.
Fuke Y; Fujita T; Satomura A; Endo M; Matsumoto K
Clin Nephrol; 2009 Feb; 71(2):110-7. PubMed ID: 19203502
[TBL] [Abstract][Full Text] [Related]
79. [Protective effect of urinastatin on cisplatin-induced cytotoxicity in the renal tubules].
Kawasaki K; Shiba R
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2273-6. PubMed ID: 2241193
[No Abstract] [Full Text] [Related]
80. Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score-matched analysis.
Miyoshi T; Hayashi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C; Nakano T; Egawa T
Support Care Cancer; 2022 Apr; 30(4):3345-3351. PubMed ID: 34984552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
